Biofrontera Inc. to Report Second Quarter 2026 Financial Results on August 13, 2026
WOBURN, Mass., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ: BFRI) ("Biofrontera" or the "Company"), a U.S. specialty dermatology company commercializing Ameluz® (aminolevulinic acid hydrochloride) Gel, 10% with the BF-RhodoLED® lamp for photodynamic therapy (PDT) of actinic keratosis, today announced that it will report financial results for the second quarter ended June 30, 2026 before the market opens on Thursday, August 13, 2026.
Management will host a conference call and webcast the same day at 10:00 a.m. Eastern Time to discuss the results and provide a business update.
Conference Call and Webcast Details
| Detail | Information |
| Date | Thursday, August 13, 2026 |
| Time | 10:00 a.m. Eastern Time |
| U.S. / Canada toll-free | 1-877-877-1275 |
| International | 1-412-858-5202 |
| Webcast | https://event.choruscall.com/mediaframe/webcast.html?webcastid=a2Bp6alz |
Participants dialing in by telephone should ask to be joined into the Biofrontera call. The webcast will be accessible beginning approximately 20 minutes prior to the start of the call.
About Biofrontera Inc.
Biofrontera Inc. (NASDAQ: BFRI) is a U.S. specialty dermatology company focused on the treatment of dermatological conditions. The Company commercializes Ameluz® (aminolevulinic acid hydrochloride) Gel, 10%, together with the BF-RhodoLED® lamp, for photodynamic therapy (PDT) in the treatment of actinic keratosis. Biofrontera Inc. has been a standalone, publicly traded company since its 2021 IPO and operates a wholly owned subsidiary, Biofrontera Discovery GmbH, in Germany. For more information, visit www.biofrontera-us.com.
Investor Contact
Ben Shamsian
Lytham Partners
shamsian@lythampartners.com
The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
This Once-Hot AI Stock Now Looks Deeply Undervalued
3 Stocks to Sell and 3 Stocks to Buy for November
Tech Stocks Sell Off as Intel, Amazon Earnings Spook Investors
The 10 Best Companies to Invest in Now
United States